Grifols (GRF.MC) Hisse Fiyat
Grifols Fiyat
Gelir, son 19 yılda yıllık bileşik %13,8 artarak 7,52 Md EUR seviyesine ulaştı. Hisse başına kâr, son 19 yılda yıllık %12,1 büyüdü. Grifols şirketinde net marj %5,3 seviyesinde bulunuyor; birkaç yıl önceki %5,4 seviyesine göre büyük ölçüde sabit kaldı. Grifols şu anda yaklaşık %1,38 temettü verimi sunuyor. Temettü dağıtım oranı, kârın yaklaşık %26 düzeyindedir. Temettü, son 18 yılda yıllık %9,3 artış gösterdi. Analistler 15,94 EUR medyan fiyat hedefi belirliyor; bu, güncel fiyatın %46,1 üzerinde bir seviyeye işaret ediyor. 21 analistten 15 tanesi hisse için alım öneriyor — genel konsensüs: Al.
Grifols hisse senedi fiyatı
Bu verilere Eulerpool API üzerinden ulaşın
Ayda 100.000 ücretsiz istek · kredi kartı yok
Grifols iş modeli ve hisse analizi
Grifols hakkında sık sorulan sorular
Grifols SA is a leading global healthcare company focused on improving the health and well-being of people worldwide. The business model of Grifols SA revolves around three main pillars. First, they are engaged in the research, development, production, and sale of plasma-derived products, including immunoglobulins, coagulation factors, and albumin. Second, their diagnostic division offers a comprehensive range of tests and instruments for clinical laboratories. Finally, Grifols SA operates a network of plasma donor centers to collect the raw material used in their plasma-derived therapies. By combining these three elements, Grifols SA ensures a sustainable and efficient business model to provide life-saving therapies to patients and contribute to the advancement of healthcare.
Grifols SA is primarily active in the healthcare industry. The company specializes in the production of plasma-derived medicines, diagnostic systems, and hospital supplies. Grifols SA operates globally, providing a wide range of products and services to healthcare professionals, hospitals, and patients. With a strong presence in the field of transfusion medicine, Grifols SA is known for its contributions in plasma therapies, blood banking, and clinical testing. As a leading player in the healthcare sector, Grifols SA maintains a commitment to advancing treatments, improving patient care, and enhancing scientific research in collaboration with healthcare professionals worldwide.
The main competitors of Grifols SA in the market include multinational pharmaceutical companies such as CSL Limited, Octapharma AG, and Takeda Pharmaceutical Company Limited.
Grifols SA is a multinational pharmaceutical and chemical company based in Spain. Established in 1940 by Dr. José Antonio Grifols Roig, the company began as a small laboratory in Barcelona. Over the years, Grifols SA has grown into a global leader in the production of plasma-derived medicines, diagnostics, and hospital supplies. Their focus on innovation, research, and development has led to numerous breakthroughs in the healthcare industry. With a strong commitment to improving patients' lives, Grifols SA has expanded its operations worldwide and currently operates in more than 100 countries. Their dedication to quality and patient care has earned them a reputable position in the healthcare sector.
Grifols SA, a renowned global healthcare company, has accomplished several significant milestones over the years. One notable achievement is its successful development and production of life-saving plasma medicines, including immunoglobulins, factor VIII, and albumin. Additionally, Grifols SA has pioneered the advancements in transfusion medicine, playing a vital role in blood purification techniques. Furthermore, the company has expanded its reach by acquiring and integrating other renowned pharmaceutical companies such as Talecris Biotherapeutics and Nat-Bioplasma. Grifols SA continues to innovate and provide critical healthcare solutions worldwide, solidifying its position as a leading player in the industry.
Grifols SA primarily operates in various countries and regions worldwide. The company has a significant presence in Spain, where it is headquartered. Additionally, Grifols has expanded its operations to other countries, including the United States, Canada, Mexico, Germany, Italy, France, the United Kingdom, Australia, Japan, and China, among others. With a global footprint, Grifols aims to provide its products and services to a diverse range of markets, contributing to its growth and success in the pharmaceutical and healthcare industry.
As a leading global healthcare company, Grifols SA values innovation, excellence, and a strong commitment to improving patients' lives. Their corporate philosophy centers around three key pillars: commitment to patients, scientific research, and sustainable development. Grifols SA strives to provide high-quality therapies and products, ensuring patient safety and meeting the evolving needs of healthcare professionals worldwide. With a focus on research and development, they aim to advance scientific knowledge and enhance treatment options. Additionally, Grifols SA prioritizes sustainability and responsible business practices, contributing to the well-being of society and the environment.
Analistler şu anda Grifols hissesi için ortalama 15,91 EUR hedef fiyat belirliyor (medyan: 15,94 EUR); bu, son fiyata göre +45,9 % anlamına gelir. Konsensüs 21 analist notuna dayanır.
21 analist şu anda Grifols hissesini değerlendiriyor: 15 al, 4 tut, 2 sat öneriyor. 2026 için analistler Grifols şirketinin 7,69 Md EUR gelir ve 0,86 EUR hisse başına kâr üretmesini bekliyor.
Grifols hissesi (GRF.MC) 10 borsada işlem görür, bunlar arasında: London (0RDU.L), SIX (Zürich) (GRF.SW), Frankfurt (OZTA.F), München (OZTA.MU), Düsseldorf (OZTA.DU), Wien (GRF.VI), Madrid (GRF.MC).
Grifols SA is a leading international company in the field of medical diagnostics and therapy. Founded in 1940, the company is based in Barcelona, Spain, and employs over 18,000 people worldwide. Grifols operates in four business areas: Bioscience, Diagnostics, Hospital, and Raw Materials. Each of these business areas offers a variety of products and services. In the Bioscience business area, Grifols is a global leader in the production of plasma proteins and biopharmaceuticals used in the treatment of serious diseases such as Alpha-1 antitrypsin deficiency, immunodeficiency, hemophilia, and thrombosis. Grifols' products are available in over 100 countries worldwide. In the Diagnostics area, Grifols develops and manufactures diagnostic tests for blood group determination, disease monitoring, and infection diagnostics. Grifols' products are used in clinical laboratories and blood banks worldwide. In the Hospital business area, Grifols offers a comprehensive range of products and services for transfusion, immunotherapy, and clinical nutrition. The company produces infusion solutions, injection products, plasma extraction devices, and clinical nutrition products. The Raw Materials business area includes the production and processing of raw materials for all of Grifols' business areas. Grifols is a global leader in the production of plasma proteins and has one of the most extensive plasma sources worldwide. Grifols is committed to offering products and services of the highest quality and continuously advancing product development. The company invests over 400 million euros in research and development every year. In addition, Grifols operates an extensive global marketing and sales organization to ensure that its products and services are available in all regions worldwide. The company works closely with regulatory authorities and regulatory institutions to ensure that its products meet the highest international standards. Overall, Grifols' business model is focused on offering high-quality products and services in various areas of medical diagnostics and therapy. With its wide range of products, strong global presence, and continuous investments in research and development, the company is well positioned to succeed in an increasingly competitive environment.
beklenen'nin Grifols hasılatı 7,69 Md EUR'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.
beklenen'nin Grifols karı 592,28 M EUR'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.
Grifols'nin Fiyat/Kazanç (F/K) oranı şu anda 12,66'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların Grifols hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.
Grifols'nin Fiyat/Satış (F/S) oranı şu anda 0,98'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve Grifols hisse senedinin değerleme metriği olarak hizmet eder.
Grifols'nin Eulerpool Kalite Puanı 5/10'dur.
Grifols'nin ISIN'i ES0171996087'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.
Grifols'nin WKN'i A2ABUQ'dir. WKN (Wertpapierkennnummer), menkul kıymetleri tanımlamak için kullanılan altı haneli bir Alman kimlik numarasıdır.
Grifols'nin ticker'ı GRF.MC'dir. Ticker sembolü, Grifols hisseleri borsada işlem görmek için kullanılır.
Grifols Hissesi
Grifols Emsaller Grubu
Grifols Ticker
Grifols FIGI
Grifols'nin tüm temel göstergeleri ve derinlemesine analizi
Grifols hissesine yönelik aktienanalizimiz, satış, kar, P/E oranı, P/S oranı, EBIT gibi önemli mali kriterleri içermekte olup, dividende bilgilerini de ele almaktadır. Ayrıca, hisseler, piyasa değeri, borçlar, özsermaye ve Grifols şirketin yükümlülükleri gibi konuları incelemekteyiz. Bu konular hakkında daha detaylı bilgilere ihtiyacınız varsa, web sitemizin alt sayfalarında kapsamlı analizler sunuyoruz: